Search Results - "Lewitt, Peter A."

Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics by LeWitt, Peter A.

“…For all its imperfections at treating Parkinson's disease (PD), orally‐administered levodopa (l‐dopa) can be regarded as the “platinum” standard of PD…”
Get full text

Metabolomic biomarkers as strong correlates of Parkinson disease progression by LeWitt, Peter A, Li, Jia, Lu, Mei, Guo, Lining, Auinger, Peggy

“…OBJECTIVE:To determine whether a Parkinson disease (PD)-specific biochemical signature might be found in the total body metabolic milieu or in the CSF…”
Get full text

Norepinephrine deficiency in Parkinson's disease: The case for noradrenergic enhancement by Espay, Alberto J., LeWitt, Peter A., Kaufmann, Horacio

“…ABSTRACT The dramatic response of most motor and some nonmotor symptoms to dopaminergic therapies has contributed to maintaining the long‐established identity…”
Get full text

Diagnostic metabolomic profiling of Parkinson's disease biospecimens by LeWitt, Peter A., Li, Jia, Wu, Kuan-Han, Lu, Mei

“…Reliable and sensitive biomarkers are needed for enhancing and predicting Parkinson's disease (PD) diagnosis. To investigate comprehensive metabolomic…”
Get full text

Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets by Espay, Alberto J, Dr, LeWitt, Peter A, Prof, Hauser, Robert A, Prof, Merola, Aristide, MD, Masellis, Mario, MD, Lang, Anthony E, Prof

“…Summary Neurogenic orthostatic hypotension and supine hypertension are common manifestations of cardiovascular dysautonomia in Parkinson's disease and related…”
Get full text

3-hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis by LeWitt, Peter A., Li, Jia, Lu, Mei, Beach, Thomas G., Adler, Charles H., Guo, Lining

“…ABSTRACT Parkinson's disease (PD) biomarkers are needed to enhance therapeutics research and to understand PD pathogenesis. Methods that simultaneously measure…”
Get full text

Are Parkinson’s disease patients referred too late for device-aided therapies and how can better informed and earlier referrals be encouraged? by Borovečki, Fran, Perković, Romana, Kovacs, Norbert, LeWitt, Peter A., Bar, Monika Rudzinska, Katzenschlager, Regina

“…In the advanced Parkinson's disease, motor and non-motor symptoms become more severe and more difficult to treat. Oral therapy may become insufficient in…”
Get full text

AAV2- GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial by LeWitt, Peter A, Prof, Rezai, Ali R, Prof, Leehey, Maureen A, Prof, Ojemann, Steven G, MD, Flaherty, Alice W, MD, Eskandar, Emad N, MD, Kostyk, Sandra K, MD, Thomas, Karen, DO, Sarkar, Atom, MD, Siddiqui, Mustafa S, MD, Tatter, Stephen B, Prof, Schwalb, Jason M, MD, Poston, Kathleen L, MD, Henderson, Jaimie M, MD, Kurlan, Roger M, Prof, Richard, Irene H, MD, Van Meter, Lori, MS, Sapan, Christine V, PhD, During, Matthew J, Prof, Kaplitt, Michael G, MD, Feigin, Andrew, Dr

“…Summary Background Gene transfer of glutamic acid decarboxylase ( GAD ) and other methods that modulate production of GABA in the subthalamic nucleus improve…”
Get full text

Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005) by LeWitt, Peter A., Guttman, M., Tetrud, James W., Tuite, Paul J., Mori, Akihisa, Chaikin, Philip, Sussman, Neil M.

“…Objective Based on new understanding of nondopaminergic pathways involved in Parkinson's disease (PD) pathophysiology, a selective adenosine A2A receptor…”
Get full text

A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease by LeWitt, Peter A., Hauser, Robert A., Grosset, Donald G., Stocchi, Fabrizio, Saint-Hilaire, Marie-Helene, Ellenbogen, Aaron, Leinonen, Mika, Hampson, Neil B., DeFeo-Fraulini, Tia, Freed, Martin I., Kieburtz, Karl D.

“…Background Although levodopa is the most effective oral PD therapy, many patients experience motor fluctuations, including sudden loss of dose effect and…”
Get full text

The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 clinical development program by LeWitt, Peter A., Stocchi, Fabrizio, Arkadir, David, Caraco, Yoseph, Adar, Liat, Perlstein, Itay, Case, Ryan, Giladi, Nir

“…Background While treatment with levodopa remains the cornerstone of Parkinson's disease (PD) management, chronic oral therapy is often associated with the…”
Get full text

Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan by Goetz, Christopher G., Fahn, Stanley, Martinez-Martin, Pablo, Poewe, Werner, Sampaio, Cristina, Stebbins, Glenn T., Stern, Matthew B., Tilley, Barbara C., Dodel, Richard, Dubois, Bruno, Holloway, Robert, Jankovic, Joseph, Kulisevsky, Jaime, Lang, Anthony E., Lees, Andrew, Leurgans, Sue, LeWitt, Peter A., Nyenhuis, David, Olanow, C. Warren, Rascol, Olivier, Schrag, Anette, Teresi, Jeanne A., Van Hilten, Jacobus J., LaPelle, Nancy

“…This article presents the revision process, major innovations, and clinimetric testing program for the Movement Disorder Society (MDS)–sponsored revision of…”
Get full text

Norepinephrine: the next therapeutics frontier for Parkinson's disease by Lewitt, Peter A

“…Tissue concentrations of norepinephrine (NE) are markedly decreased in various regions of the Parkinson's disease (PD) brain. As in the substantia nigra pars…”
Get full text

Getting an earful of stimulation: A novel means for neuromodulation of Parkinson disease by LeWitt, Peter A.

Get full text

Levodopa for the Treatment of Parkinson's Disease by LeWitt, Peter A

“…A 62-year-old man presents with Parkinson's disease, and treatment with levodopa is recommended. Levodopa, a naturally occurring amino acid that is metabolized…”
Get full text

Long-term follow-up of a randomized AAV2- GAD gene therapy trial for Parkinson's disease by Niethammer, Martin, Tang, Chris C, LeWitt, Peter A, Rezai, Ali R, Leehey, Maureen A, Ojemann, Steven G, Flaherty, Alice W, Eskandar, Emad N, Kostyk, Sandra K, Sarkar, Atom, Siddiqui, Mustafa S, Tatter, Stephen B, Schwalb, Jason M, Poston, Kathleen L, Henderson, Jaimie M, Kurlan, Roger M, Richard, Irene H, Sapan, Christine V, Eidelberg, David, During, Matthew J, Kaplitt, Michael G, Feigin, Andrew

“…We report the 12-month clinical and imaging data on the effects of bilateral delivery of the glutamic acid decarboxylase gene into the subthalamic nuclei (STN)…”
Get full text

Levodopa therapy for Parkinson disease: A look backward and forward by LeWitt, Peter A, Fahn, Stanley

“…Although levodopa is widely recognized as the most effective therapy for Parkinson disease (PD), its introduction 5 decades ago was preceded by several years…”
Get full text

Unmet needs in Parkinson disease: Motor and non-motor by LeWitt, Peter A., Chaudhuri, K. Ray

“…Compared to other neurodegenerative diseases, Parkinson's disease (PD) is distinctive in terms of marked symptomatic variability and prognosis, as well as for…”
Get full text

Dopamine Metabolite Biomarkers and Testing for Disease Modification in Parkinson Disease by LeWitt, Peter A

Get more information

Cellular immune response to intrastriatally implanted allogeneic bone marrow stromal cells in a rat model of Parkinson's disease by Camp, Dianne M, Loeffler, David A, Farrah, Diane M, Borneman, Jade N, LeWitt, Peter A

“…Marrow stromal cells (MSC), the non-hematopoietic precursor cells in bone marrow, are being investigated for therapeutic potential in CNS disorders. Although…”
Get full text